• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Flamel Technologies S.A. (FLML) - Financial and Strategic SWOT Analysis Review - Product Image

Flamel Technologies S.A. (FLML) - Financial and Strategic SWOT Analysis Review

  • Published: May 2013
  • 39 pages
  • GlobalData

FEATURED COMPANIES

  • Alkermes, Inc.
  • Ambrx, Inc.
  • ANDRX Corporation
  • Depomed, Inc.
  • DURECT Corporation
  • Nektar Therapeutics
  • MORE

Summary

Flamel Technologies S.A. (Flamel) is a biopharmaceutical company which conducts the development of drugs to tackle unmet medical needs. The key technologies of the company include Medusa, liquitime, Micropump, Trigger Lock and Delivax. The company is developing drugs like IFN-a XL, FT-105, IL-2 XL, Tigecycline XL, hGH XL and GLP-1 XL using Medusa based technology; drugs dedicated to those children and elder patients who have difficulty in swallowing tablets using LiquiTime technology among others. It also develops, marketed and sold Coreg CR using Micropump technology. It secures patents and other intellectual property rights over its innovations and developments and holds various patents.

Flamel Technologies S.A. Key Recent Developments

Mar 22, 2013: US District Court Dismisses Class Action Case Against Flamel Technologies
Feb 28, 2013: Flamel Technologies Reports Revenue Of $26.1m In 2012
Nov 05, 2012: Flamel Technologies Reports Revenue Of $5.4m In Q3 2012
Oct 18, 2012: Flamel Technologies Announces FDA Acceptance Of New Drug Application
Jul 25, 2012: Flamel Technologies Reports Total Revenue Of $6.1m For Q2 2012

This comprehensive READ MORE >

List of Tables
List of Figures
Section 1 - About the Company
Flamel Technologies S.A. - Key Facts
Flamel Technologies S.A. - Key Employees
Flamel Technologies S.A. - Key Employee Biographies
Flamel Technologies S.A. - Major Products and Services
Flamel Technologies S.A. - Pharmaceutical Pipeline Products Data
Flamel Technologies S.A., Pipeline Products by Therapy Area
Flamel Technologies S.A., Pipeline Products by Development Phase
Flamel Technologies S.A. - History
Flamel Technologies S.A. - Company Statement
Flamel Technologies S.A. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Flamel Technologies S.A. - Key Manufacturing Facilities
Section 2 – Company Analysis
Flamel Technologies S.A. - Business Description
Flamel Technologies S.A. - SWOT Analysis
SWOT Analysis - Overview
Flamel Technologies S.A. - Strengths
Strength - Unique Polymer-Based Drug Delivery Platforms
Strength - Coreg CR-Lead product
Flamel Technologies S.A. - Weaknesses
Weakness - Dependence on Limited Customers
Weakness - Dependence on Single Manufacturing Unit
Flamel Technologies S.A. - Opportunities
Opportunity - Emerging Markets
Opportunity - Need for Novel Delivery Systems
Opportunity - Changing Demographics
Flamel Technologies S.A. - Threats
Threat - Intense Competition
Threat - Uncertain R&D Outcomes
Threat - Growing Parallel Trade
Flamel Technologies S.A. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Flamel Technologies S.A., Recent Deals Summary
Section 5 – Company’s Recent Developments
Flamel Technologies S.A., Recent Developments
Mar 22, 2013: US District Court Dismisses Class Action Case Against Flamel Technologies
Feb 28, 2013: Flamel Technologies Reports Revenue Of $26.1m In 2012
Nov 05, 2012: Flamel Technologies Reports Revenue Of $5.4m In Q3 2012
Oct 18, 2012: Flamel Technologies Announces FDA Acceptance Of New Drug Application
Jul 25, 2012: Flamel Technologies Reports Total Revenue Of $6.1m For Q2 2012
May 07, 2012: Flamel Technologies Reports Revenue Of $7.3m In Q1 2012
Mar 14, 2012: Flamel Technologies Reports Revenue Of $8.6m In Q4 2011
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
Flamel Technologies S.A., Key Facts
Flamel Technologies S.A., Key Employees
Flamel Technologies S.A., Key Employee Biographies
Flamel Technologies S.A., Major Products and Services
Flamel Technologies S.A., Number of Pipeline Products by Therapy Area
Flamel Technologies S.A., Number of Pipeline Products by Development Stage
Flamel Technologies S.A., Pipeline Products By Therapy Area and Development Phase
Flamel Technologies S.A., History
Flamel Technologies S.A., Subsidiaries
Flamel Technologies S.A., Key Manufacturing Facilities
Flamel Technologies S.A., Key Competitors
Flamel Technologies S.A., Ratios based on current share price
Flamel Technologies S.A., Annual Ratios
Flamel Technologies S.A., Interim Ratios
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Flamel Technologies S.A., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Flamel Technologies S.A., Pipeline Products by Therapy Area
Flamel Technologies S.A., Pipeline Products by Development Phase
Flamel Technologies S.A., Performance Chart (2007 - 2011)
Flamel Technologies S.A., Ratio Charts
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013

Enzon Pharmaceuticals, Inc.
ANDRX Corporation
Ambrx, Inc.
DURECT Corporation
Nektar Therapeutics
Human Genome Sciences, Inc.
Depomed, Inc.
SkyePharma PLC
Alkermes, Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS